JPRN-UMIN000005662已完成2 期
Efficacy and safety of a 5-day regimen of azacitidine in patients with low-risk myelodysplastic syndrome - Efficacy and safety of a 5-day regimen of azacitidine in patients with low-risk myelodysplastic syndrome
Department of Hematology, Kinki University School of Medicine0 个研究点目标入组 50 人开始时间: 2011年5月30日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with simultaneous multiple cancers. 2. Patients with history of hyper- sensitivity to mannitol 3. Patients with poorly-controlled infection requiring intensive care with antibiotics and antifungals. 4. Patients with poorly-controlled diabetes. 5. Patients with severe psychiatric disorder. 6. Pregnant or lactating females. 7. Patients with positive serology for HBs antigen, HCV antibody or HIV antibody. 8. Patients who is deemed as ineligible for this study by investigator.
研究者
相似试验
进行中（未招募）
1 期
Comparison between 5 – azacytidine treatment and 5 – azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availabilityEUCTR2010-018467-42-DEniversity Medical Center Hamburg-Eppendorf110
招募中
3 期
ong-term treatment with azithromycin to prevent bronchiectasis and recurrent cough (LEAP-Cough)Chronic wet coughRespiratory - Other respiratory disorders / diseasesACTRN12623000098639Queensland University of Technology274
进行中（未招募）
不适用
Clinical and biological evaluation of azacitidine in transfusion-dependent patients with Low and intermediate-1 risk MDS, and low-risk CMML, who are either refractory to or not eligible for treatment with erythropoietin +/- G-CSFow and intermediate-1 risk MDS, and low-risk CMML.MedDRA version: 12.0Level: LLTClassification code 10009018Term: Chronic myelomonocytic leukaemiaMedDRA version: 12.0Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2009-011483-11-DKMDSG30
进行中（未招募）
不适用
Clinical and biological evaluation of azacitidine in transfusion-dependent patients with Low and intermediate-1 risk MDS, and low-risk CMML, who are either refractory to or not eligible for treatment with erythropoietin +/- G-CSFow and intermediate-1 risk MDS, and low-risk CMML.MedDRA version: 12.0Level: LLTClassification code 10009018Term: Chronic myelomonocytic leukaemiaMedDRA version: 12.0Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2009-011483-11-SEMDSG30
进行中（未招募）
不适用
?Clinical and biological effects of 5-Azacitidine five days/monthly schedule in symptomatic low-risk myelodysplastic syndromes (MDSs)? - MDS0706EUCTR2007-003943-55-ITAZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA